Dr. med. Jule Taubmann



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells (2025) Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, et al. Journal article Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry (2025) Albrecht A, Taubmann J, Minopoulou I, Hatscher L, Kleinert S, Mühlensiepen F, Welcker M, et al. Journal article Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients (2025) Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, Park S, et al. Journal article Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma (2025) Müller F, Schwingen NR, Hagen M, Scholz J, Aigner M, Wirsching A, Taubmann J, et al. Journal article CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series (2024) Auth J, Müller F, Völkl S, Bayerl N, Distler JH, Tur C, Raimondo MG, et al. Journal article Comment on: Rescue therapy of anti-synthetase syndrome with CD19-targeted CART cells after failure of several B cell-depleting antibodies: reply. (2024) Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kretschmann S, Atzinger A, et al. Journal article Advancements and challenges in CAR T cell therapy in autoimmune diseases (2024) Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, et al. Journal article, Review article CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher? (2024) Hagen M, Wirsching A, Bohr D, Taubmann J, Müller F, Mackensen A, Grieshaber Bouyer R, Schett G Journal article Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production (2024) Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan CD, Cheng JK, et al. Journal article CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. (2024) Taubmann J, Müller F, Mutlu MY, Völkl S, Aigner M, Bozec A, Mackensen A, et al. Journal article, Review article